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Background: Epigenetic control using histone deacetylase (HDAC) inhibitors is a promising therapy for lymphomas.
Insights into the anti-proliferative effects of HDAC inhibitors on diffuse large B-cell lymphoma (DLBCL) and further
understanding of the underlying mechanisms, which remain unclear to date, are of great importance.
Methods: Three DLBCL cell lines (DoHH2, LY1 and LY8) were used to define the potential epigenetic targets for
Trichostatin A (TSA)-mediated anti-proliferative effects via CCK-8 assay. Cell cycle distribution and apoptosis were
detected by flow cytometry. We further investigated the underlying molecular mechanisms by examining
expression levels of relevant proteins using western blot analysis.
Results: TSA treatment inhibited the growth of all three DLBCL cell lines and enhanced cell cycle arrest and
apoptosis. Molecular analysis revealed upregulated acetylation of histone H3, α-tubulin and p53, and
dephosphorylation of pAkt with altered expression of its main downstream effectors (p21, p27, cyclin D1 and Bcl-2).
HDAC profiling revealed that all three cell lines had varying HDAC1–6 expression levels, with the highest expression
of all six isoforms, in DoHH2 cells, which displayed the highest sensitivity to TSA.
Conclusion: Our results demonstrated that the HDAC inhibitor TSA inhibited DLBCL cell growth, and that cell lines
with higher expression of HDACs tended to be more sensitive to TSA. Our data also suggested that inhibition of
pAkt and activation of p53 pathway are the main molecular events involved in inhibitory effects of TSA.
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Diffuse large B-cell lymphoma (DLBCL) is the most com-
mon type of non-Hodgkin’s lymphoma. Rituximab, an
anti-CD20 antibody, administered as induction or main-
tenance therapy in combination with CHOP significantly
prolonged event-free survival of DLBCL. However, contin-
ued use of rituximab has resulted in CD20 negative trans-
formation of tumor cells and failure to demonstrate* Correspondence: xyzhou100@yahoo.com
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reproduction in any medium, provided the orbenefit [1]. Therapeutic challenges persist, and investiga-
tions of new targeted strategies are urgently needed.
The histone deacetylase (HDAC) enzymes remove acetyl
groups from histone and non-histone proteins, and lead
to the formation of a compacted and transcriptionally-
repressed chromatin structure. As a result, the global gene
expression profile is modified and cellular function is al-
tered via multiple pathways. Aberrant HDAC expression
in cancers suggests that HDACs are potential targets for
epigenetic treatment [2].
Class 1 and 2 histone deacetylase expression in a panel
of lymphoma cell lines and tissue sections was previously
reported [3], and clinical evaluation indicates that lymph-
oid malignancies are more sensitive to HDAC inhibitors. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibitors have been widely used in clinical trials in lymph-
oma, including peripheral T-cell lymphoma, mantle cell
lymphoma, and DLBCL [5]. Furthermore, HDAC inhibi-
tors, e.g. Romidepsin (Istodax, Celgene, Summit, USA) and
Vorinostat (Zolinza, Merck, Whitehouse Station, USA),
have been accepted by the US FDA for treating advanced
and refractory cutaneous T-cell lymphoma (CTCL) [6].
Although clinical trials have proven suppressing effects
of selected inhibitors on DLBCL patients, no HDAC in-
hibitors have been approved for the treatment of DLBCL
[7]. Insights into the anti-proliferative effects of HDAC
inhibitors on DLBCL, and further understanding of the
underlying mechanisms are of great importance. In this
study, we evaluated the effects of Trichostatin A (TSA),
a hydroxamic acid derivative that inhibits most HDAC
isoforms, and elucidated the molecular mechanisms
underlying the subsequent altered biological behavior of
DLBCL cell lines. We identified varied expression levels
of HDACs in DoHH2, LY1 and LY8 cell lines, and thus
we selected these lines for our investigation.
Results
Effects of TSA on growth inhibition in all three DLBCL cell
lines induced by cell cycle arrest and apoptosis
Three DLBCL cell lines (DoHH2, LY1 and LY8) were
treated with varying concentrations of TSA. Growth of
all three DLBCL cell lines was inhibited by TSAFigure 1 Growth inhibition of DLBCL cell lines by TSA. (A) DoHH2, (B)
TSA for 48 h to examine dose-dependent inhibitory effects. Probit Regressi
LY1 and LY8 cells, respectively. (C) Cell growth curves of DoHH2 (treated w
treated with DMSO were used as controls. Cell viability of DoHH2, LY1 and
mean ± SD of three independent experiments performed in triplicate.treatment in a dose-dependent manner (Figure 1A, B).
A much higher drug concentration was needed to sig-
nificantly inhibit the growth of both LY1 and LY8 cells
compared with DoHH2 cells. Probit Regression analysis
of results after 48 h of TSA treatment revealed IC50
values for LY1, LY8 and DoHH2 cells of 250 nM,
350 nM and 45 nM, respectively, indicating DoHH2
cells as the most sensitive to TSA. From these results,
we selected a treatment level for DoHH2 cells of 50 nM
TSA, and 300 nM TSA for LY1 and LY8 cells for all
subsequent experiments. After 48 h treatment, the rela-
tive cell viability of DoHH2, LY1 and LY8 cells declined
to 40%, 60% and 41%, respectively, and declined further
to 21%, 19% and 6% after 72 h treatment, indicating that
TSA exhibits its inhibitory effects in DLBCL cells in a
time-dependent manner (Figure 1C, D).
We next examined the cell cycle phase distribution
after TSA treatment. The percentage of untreated
DoHH2 cells at G1 phase was 32.73%, which increased
to 59.97% after 24 h TSA treatment, while the percent-
age of S phase cells decreased from 49.50% to 23.30%.
The percentage of LY1 cells in G1 phase increased from
33.92% to 53.74% after TSA treatment, while S phase
cells declined from 49.60% to 26.60% after 24 h treat-
ment. However, in LY8 cells, the percentage of G2 phase
cells increased from 17.76% to 41.65%, and S phase de-
creased from 45.20% to 26.80%, indicating a G2/M ar-
rest (Figure 2A). A significant G0/G1 arrest was inducedLY1 and LY8 cells were treated with the indicated concentrations of
on determined IC50 values of 45 nM, 250 nM and 350 nM in DoHH2,
ith 50 nM TSA), (D) LY1 and LY8 cells (treated with 300 nM TSA). Cells
LY8 cells was determined by CCK-8 assay. Results are displayed as
Figure 2 Effects of TSA on cell cycle in DLBCL cells. (A) PI staining and flow cytometric analysis of cell cycle distribution in DoHH2, LY1 and
LY8 cells after treatment with vehicle or indicated concentration of TSA after 24 h. One representative experiment is shown for each cell line.
(B) Results displayed as mean ± SD of three independent experiments performed in triplicate. * P < 0.05 and ** P < 0.01 compared with
vehicle treatment.
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cells, with a corresponding decrease of cells in S phase
(P < 0.01) (Figure 2B). A consistent induction of G0/G1
arrest (P < 0.05) and corresponding S phase reduction
(P < 0.01) were observed in LY1 cells after 24 h treatment
(Figure 2B). However, we detected a G2/M arrest
(P < 0.05) and relevant S phase decline (P <0.01) in LY8
cells (Figure 2B).
The Annexin V/PE-7AAD dual staining assay showed
that 24 h treatment with TSA induced apoptosis in both
LY1 cells (1.4% vs. 20.6%) and LY8 cells (9.4% vs. 28.2%)
(Figure 3A). As shown in Figure 3B, significant apop-
tosis was induced in LY1 and LY8 cells after 24 h TSA
exposure relative to control groups (P < 0.05). Further-
more, apoptosis occurred earlier in LY8 cells than in
LY1 cells (18 h vs. 24 h, data not shown). However, no
significant apoptosis was observed in DoHH2 cells upon
TSA treatment (50 nM) (Figure 3B).HDAC expression in DLBCL cell lines
We next determined the expression profile of the main
HDAC isoforms in each cell line. Western blot analysis
revealed differential expression levels of Class I
HDACs (HDAC1, 2 and 3) and Class II HDACs
(HDAC4, 5 and 6) in the three DLBCL lines
(Figure 4A). All three cell lines strongly expressed
HDAC1 and HDAC2. Higher expression levels of
HDAC3 and HDAC4 were found in DoHH2 and LY1
cells compared to LY8 cells. HDAC5 was only found in
DoHH2 cells and at very high levels. DoHH2 cells also
expressed the highest levels of HDAC6, while moder-
ate to weak expression was observed in LY1 and LY8
cells. Together these data showed that the highest ex-
pression levels of all six HDAC isoforms were detected
in DoHH2 cells, suggesting that the high sensitivity to
TSA in DoHH2 cells might be due to the high expres-
sion of HDACs.
Figure 3 Effects of TSA on apoptosis in DLBCL cells. (A) Annexin V/PE-7AAD dual staining and flow cytometric analysis of early and late
apoptosis of LY1, LY8 and DoHH2 cells treated with TSA (concentrations as indicated) for 24 h. One representative experiment shown for each
cell line. The lower right quadrant shows percentage of cells in early apoptosis, the upper right quadrant indicates percentage of cells in late
apoptosis, and the lower left quadrant shows percentage of vital cells. (B) Percentages of early apoptosis cells are displayed as mean ± SD of
three independent experiments performed in triplicate. * P < 0.05 compared with vehicle treatment.
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proteins in DLBCL cells
To further examine the effects of TSA, we evaluated
acetylation of HDAC-related biomarkers, histone H3
and α-tubulin. Histone H3 (HH3) is one of the main
substrates of Class I HDAC and α-tubulin is a target of
HDAC6. Both acetyl-histone H3 and acetyl-α-tubulin
levels were elevated in the three cell lines after 1 h treat-
ment (Figure 4B), suggesting that TSA could inhibit
their deacetylation. Though a non-histone protein, p53
is also a substrate of HDAC and its acetylation enhances
its stability and extends its half life [8]. Alterations of
acetyl-p53 levels were found in LY1 and LY8 cells
(Figure 4B). After 1 h incubation with TSA (300 nM),
acetyl-p53 levels increased in LY1 and LY8 cells, which
express mutant p53 [9]. In contrast, in DoHH2 cells,
which express wild-type p53 [10], 50 nM TSA did notcause any apparent changes in acetyl-p53 levels and
downregulated p53 expression (Figure 4B).
Dephosphorylation of pAkt and subsequent negative
regulation of its downstream effectors p21, p27 and
cyclin D1 after TSA treatment
Overexpression of pAkt is commonly observed in DLBCL
[11]. After TSA treatment, downregulation of pAkt was
consistently detected in all three cells lines (Figure 5A).
Both p21 and p27, downstream targets of pAkt, showed
variable expression in the three cell lines (Figure 5A).
Levels of p27 were continually upregulated and peaked at
6 h in DoHH2 and LY1 cells. In LY8 cells, expression of
p27 increased after 2 h and declined after 6 h of TSA ex-
posure. Expression of p21 significantly increased after 1 h
incubation with TSA in LY1 and LY8 cells, while DoHH2
cells showed no apparent changes in p21 levels. Cyclin
Figure 4 Expression of HDAC1–6 in DLBCL cells and effects of TSA on its substrates. (A) Expression of HDAC1–6 in three DLBCL cell lines
by western blot analysis. (B) Expression of substrates of TSA, including histone H3, α-tubulin and p53, and their acetylation patterns at different
time points after TSA treatment.
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was downregulated in LY1 and LY8 cells, but not in
DoHH2 cells.
Downregulation of Bcl-2 and cleavage of PARP induced
by TSA
Bcl-2, an anti-apoptotic protein, was previously reported
to be overexpressed in DLBCL [12], which was confirmed
in the cell lines we tested (Figure 5C). We next examined
the expression level of Bcl-2 before and after TSA treat-
ment. As indicated in Figure 5B, we found downregulated
Bcl-2 expression levels in LY1 and LY8 cells after TSA
treatment with earlier peak levels in LY8 cells, in which
the apoptotic response was detected earlier than in LY1
cells. However, in DoHH2 cells, Bcl-2 was upregulated
only for 12 h and then returned to previous levels. PARP
is a 116 kDa nuclear poly (ADP-ribose) polymerase, and
its cleaved fragment serves as a marker for cells undergo-
ing apoptosis. Cleaved PARP (89 kDa) was found in LY1
and LY8 cells in which apoptosis was detected by Annexin
V/PE-7AAD dual staining, while no cleaved fragment was
detected in DoHH2 cells, in which apoptosis did not occur
(Figure 5B).
Discussion
Epigenetic regulation of gene expression via acetylation
of histone and non-histone proteins is a new and pro-
mising therapeutic strategy [13]. Despite research of pro-
posed mechanisms of the anti-proliferative effects of
HDAC inhibitors on lymphoid malignancies [14,15], the
exact effects and mechanisms in DLBCL remain unclear.
Treatment and clinical trials of lymphoma using HDAC
inhibitors remains empiric.
To obtain insights into the mechanisms and specificity
of HDAC inhibitors toward lymphoma cells, we treated
three DLBCL cell lines with a pan-HDAC inhibitor, TSA.
TSA, which has a chemical structure similar to Vorinostat
(Zolinza), is a hydroxamate-based agent that belongs tothe largest group of HDACi. It has been reported to have
pleiotropic effects on tumor cells and suppresses cell
growth, which contributes to its pan-HDAC inhibitory
properties. Although its side effects and toxicity have li-
mited its clinical use [16], TSA is still an ideal tool and
representative of the pan-HDAC inhibitors used to analyze
the underlying mechanisms of the anti-proliferation effects
of these inhibitors in in vitro studies.
TSA was found to exert a potent anticancer activity on
human tongue squamous cell carcinoma cells [17]. An-
other in vitro study in prostate cancer cells showed that
TSA led to G2/M cell cycle disruption and apoptosis in
LNCaP cells [18]. TSA was also reported to inhibit the
growth of uveal melanoma cells with a significant reduc-
tion of viable cells and increased apoptosis [19]. In our
study, we demonstrated the growth inhibitory effects of
TSA in three DLBCL cell lines, both in a dose-dependent
and time-dependent manner. Cell cycle arrest in G0/G1
phase was observed in treated DoHH2 and LY1 cells,
while a significant G2/M phase delay was seen in LY8 cells,
in which apoptosis occurred earlier compared to the other
two cell lines. Cell cycle arrest and apoptosis may be the
basis for the subsequent growth inhibition observed in
these cells. The increasing evidence of anti-proliferation
effects of hydroxamate-based HDAC inhibitors indicates
these to be a category of promising anti-tumor agents.
Aberrant expression of HDACs has been previously
detected by immunostaining in various tumors [2]. How-
ever, only hematological malignancies appear to be particu-
larly sensitive to HDAC inhibitor therapy [13]. Expression
of HDACs in lymphoid malignancies was previously
reported [3,20]. Gloghini et al. evaluated the expression of
HDAC class 1 and 2 in cell lines and primary tissues from
different histotypes of human lymphomas and found the
most frequently altered HDAC expression was HDAC6
[3]. High expression of HDAC6 correlated with a favorable
outcome in CTCL [20]. In a more recent study, Marquard
et al. discovered a correlation between favorable outcome
Figure 5 Effects of TSA on cell cycle arrest and apoptosis proteins in DLBCL cells. (A) Effect of TSA in DoHH2 (50 nM), LY1 and LY8 cells
(300 nM) on pAkt and its downstream targets as assessed by western blot. (B) Western blot analysis of apoptosis regulators Bcl-2 and PARP in
TSA-treated cells. Arrowhead indicates the cleaved product of PARP. (C) Expression of Bcl-2 in DLBCL cell lines.
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tients [21]. However, the mechanisms underlying HDAC6
effects on patients’ survival remains unknown. In this
study, our expression profiling of HDAC1–6 in three
lymphoma cell lines found the highest expression level of
all six isoforms in DoHH2 cells, which were more sensitive
to TSA. Our results suggest that HDAC expression level
may correlate with HDAC inhibitor sensitivity. Among all
six isoforms, HDAC6 displayed significant variability in all
three cell lines. The correlation between high HDAC6
levels in DLBCL cells and sensitivity to TSA should be
further investigated with RNAi-mediated knockdown of
HDAC6 to examine whether the knockdown reverses
the sensitivity. HDAC6 is one of the targets of pan-
HDACi. Its high expression in DLBCL suggests HDAC6
might be a potential therapeutic target for the treatment
of lymphoid malignancies, since it plays a critical role in
the cellular clearance of misfolded proteins via formation
of aggresomes and autophagy [22,23]. Tubacin, a selective
HDAC6 inhibitor, has been reported to have anti-
proliferative effects and induce apoptosis in acute lympho-
blastic leukemia (ALL) cells. Treatment with tubacin led
to the induction of apoptotic pathways in both pre-B and
T cell ALL cells [24] and induced EBV-positive Burkittlymphoma cell death [25]. The effects of HDAC6-selective
inhibitors on DLBCL cells, however, had been previously
unclear and the exact function of HDAC6 in DLBCL had
remained unknown.
The p53 transcription factor, a non-histone protein, is
another substrate of HDACs. In our study, p53 acetylation
at Lys382 was higher in LY1 and LY8 cells. Mutation of
p53 gene is a common genetic alteration in lymphoma
[26]. LY1 and LY8 cells harbor a mutated form of p53, but
the mutation did not interfere with the observed enhanced
acetylation at Lys382. These cells exhibited stable expres-
sion levels of mutant p53, and its acetylation increased in
response to TSA. According to the allosteric model, acetyl-
ation of p53 causes p53 conformational changes to activate
the DNA binding domain and induce enhanced transcrip-
tional activity [27], leading to activation of cell cycle arrest
and apoptosis. However, Yan et al. reported that mutant
p53 transcription was suppressed by HDACi via HDAC8
in HaCaT cells (human keratinocyte cells) and SW480 cells
(human colorectal cells) [28]. These cell lines contain p53
mutants different from LY1 and LY8 cells, with mutations
distinct from p53 acetylation sites. Acetylation of wild-type
p53 increases its stability [8]. However, no obvious
upregulation of acetyl-p53 was observed in DoHH2 cells
Cai et al. Cancer Cell International 2013, 13:57 Page 7 of 9
http://www.cancerci.com/content/13/1/57after TSA treatment, and the level of wild-type p53 pro-
tein appeared to be unstable and declined in a time-
dependent manner. Alcendor et al. reported a similar
phenomenon in their research, showing that p53 acetyl-
ation as well as transcriptional activity of p53 was not in-
creased by TSA in cardiac myocytes [29]. Decrease of
wild-type p53 protein might be due to the regulation of
HDAC inhibitors on p53 transcription. Peltonen et al. dis-
covered that TSA stabilized wild-type p53 in melanoma
cell lines, but p53 protein accumulation was overridden by
simultaneous downregulation of p53 mRNA, leading to a
decrease in p53 protein [30]. The mechanisms of p53
acetylation on both wild-type and mutant proteins in dif-
ferent tumors after various HDACi exposure requires fur-
ther investigation.
The Akt pathway plays an important role in cell
growth, and its activation is common in tumors [31]. Inhib-
ition of overphosphorylated Akt is a promising target ther-
apy in colorectal cancer [32]. We observed pAkt
overexpression in all three cell lines and subsequent
downregulation after TSA treatment. A similar phenomenon
was reported in other studies. Chen et al. demon-
strated that HDACi caused Akt dephosphorylation in
U87MG glioblastoma and PC-3 prostate cancer cells
by disrupting HDAC-protein phosphatase 1 (PP1)
complexes [33]. LBH, another HDACi with a chemical
structure similar to TSA, mediated Akt dephosphory-
lation in DLBCL DHL-6 cells through increased bind-
ing of PP1 to Akt [34]. We further studied the
downstream targets in the Akt pathway. Upregulation
of p21 was previously commonly reported, with less
data on p27 [14]. Repression of cyclin D1 from
HDAC inhibitors was reported in mantle cell lymph-
oma [35]. In our study, we found more significant al-
terations of p27 and cyclin D1 than p21 after TSA
treatment. Both p21 and p27 were upregulated, and
cyclin D1 was downregulated with decreasing expres-
sion of pAkt, which may account for the eventual cell
cycle delay.
TSA also induces cell apoptosis in LY1 and LY8 cells.
Bcl-2, an anti-apoptosis regulator, was found to be
downregulated after TSA treatment in LY1 and LY8 cells.
In normal germinal centers, Bcl-2 is usually inactivated,
rendering centroblasts and centrocytes susceptible to apop-
tosis. Abnormal retention of Bcl-2 leads to cells that do not
die, thereby predisposing cells to malignant transformation.
In our study, western blot analysis showed that the repres-
sion of Bcl-2 occurred at the translational level in LY1 and
LY8 cells after TSA treatment. Its downregulation may be
the combined effect of Akt dephosphorylation and p53
acetylation caused by TSA. However, Bcl-2 alteration in
DoHH2 cells was quite different with LY1 and LY8 cells.
Bcl-2 gene rearrangement was previously reported in
DoHH2, LY1 and LY8 cells [36,37]. However, there is nodetailed information regarding Bcl-2 amplification in the li-
terature. Our unpublished data showed that all three cell
lines do not have apparent Bcl-2 gene amplification. One
reason for the differential effects on Bcl-2 may be due to
different levels of p53 acetylation. Low p53 acetylation may
contribute to DoHH2 cells’ resistance to apoptosis after
TSA treatment at IC50. The exact mechanisms underlying
this process need to be further investigated.
Conclusion
This investigation addressed the inhibitory effects and
underlying mechanisms of TSA, a pan-HDAC inhibitor, in
DLBCL cells. TSA suppressed the growth of all three
DLBCL cell lines by enhanced G0/G1 or G2/M arrest and
possible apoptosis. Expression levels of HDACs varied in
the three cell lines, with DoHH2 cells exhibiting the
highest expression of all six isoforms of HDAC1–6.The
expression levels of HDACs may be associated with TSA
sensitivity. Upregulated acetylation of histone H3, α-
tubulin and p53 and dephosphorylation of pAkt with alter-
ations of its main downstream effectors (p21, p27, cyclin
D1 and Bcl-2 proteins) suggested that inhibition of Akt
and activation of the p53 pathway may be the main mo-
lecular events involved in the TSA inhibitory effects. Our
results have offered evidence supporting the development
of HDAC inhibitors to combat DLBCL more efficiently.
Studies in more DLBCL cell lines treated with different
HDACi are needed to provide more substantial evidence
and clarify the roles and mechanisms of HDACi on
DLBCL to enhance their clinical applicability.
Methods
Cell lines and culture conditions
Three human DLBCL cell lines, LY1, LY8 and DoHH2,
were used in this study. LY1 and LY8 cells were kindly pro-
vided by Dr B. Hilda Ye (Albert Einstein College of Medi-
cine, USA) and grown in IMDM medium (Gibco, Grand
Island, USA) supplemented with 10% FBS (HyClone,
Logan, USA). DoHH2 cells were a gift from Prof. Mingzhi
Zhang (The First Affiliated Hospital of Zhengzhou University,
PRC) and cultured in RPMI1640 (HyClone) containing
10% FBS. Cells were grown and maintained at 37°C in a
5% CO2 humidified atmosphere.
Reagents and treatments
TSA (Sigma-Aldrich, Taufkirchen, Germany) was dissolved
in DMSO (Sigma-Aldrich) as a 5 μM stock solution,
aliquoted and stored at −20°C. Control cells were treated
with DMSO and analyzed in parallel in each experiment.
DoHH2, LY1 and LY8 cells were treated with TSA at con-
centrations ranging from 5 nM to 1000 nM for 24–72 h.
Cell viability was determined by the cell counting kit-8
(CCK-8, Dojindo, Kumamoto, Japan) and fifty percent
growth inhibition (IC50) of a 48 h TSA exposure in each
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SPSS16.0. From these results, we selected the following
treatment levels for subsequent experiments: 50 nM TSA
for DoHH2 cells, and 300 nM TSA for LY1 and LY8
cells.
Cell proliferation assay
Cell proliferation was assessed using the CCK-8 assay
according to the manufacturer’s instructions. Cells (100 μl,
5 × 105 cells/ml) were seeded into a 96-well plate and
cultured in RPMI1640 supplemented with 10% FBS
containing concentrations of TSA ranging from 0 to
1000 nM. The plate was incubated in a humidified incu-
bator (37°C, 5% CO2) for 24–72 h. Four hours before
measuring the absorbance, 10 μl of the CCK-8 solution
was added into each well. Cell viability was obtained as
the percentage of viable cells relative to untreated cells
under the absorbance at 450 nm in a microplate reader
(Biotek Instrument, Winooski, USA). Two control wells
without cells were prepared and average absorbance of
the control wells was subtracted from that of the corre-
sponding sample wells. Each experiment was performed
in triplicate.
Cell cycle analysis
Cells incubated with or without TSA were fixed gently in
absolute ethanol overnight at −20°C. After resuspension in
PBS containing 5 μg/mL propidium iodide (Sigma) and
100 μg/ml RNase A (Takara Biotechnology, Dalian,
China), cells were incubated in the dark for 15 min at
room temperature and subjected to analysis on a Flow
Cytometer Cytomics FC500 (Beckman Coulter, Brea,
USA). A total of 3 × 104 events were counted from each
sample. Cell cycle distribution was calculated using CXP
Software (Beckman Coulter), with the number of gated
cells in G1, S and G2 phase presented as a percentage.
Each experiment was performed in triplicate.
Apoptosis assay
After incubation with or without TSA, cells were harvested
at the indicated time. Apoptotic populations were quanti-
fied using the dual staining Annexin V/PE-7AAD apoptosis
detection kit (BD Biosciences, San Diego, USA) according
to the manufacturer’s instructions before flow cytometric
analysis. At least 1.5 × 104 events were counted. The per-
centage of apoptotic cells in each quadrant was calculated
using CXP Software. Each experiment was performed
in triplicate.
Western blot analysis
Cells were harvested and lysed, and total protein concen-
trations of cell lysates were determined by the BCA
Protein Assay Kit (Pierce Biotechnology, Rockford, USA).
Protein samples (30 μg) were separated by 12% SDS-PAGE and transferred onto a polyvinylidene fluoride
membrane (Millipore, Billerica, USA). The membrane was
blocked in Tris-buffered saline containing 5% bovine
serum albumin and 0.1% Tween at room temperature for
3 h, incubated with diluted primary antibody overnight at
4°C with gentle shaking, and then incubated with secon-
dary antibody for 1 h at room temperature. The following
primary antibodies were used for analysis: Ac-Histone H3
(Lys9, C5B11), Histone H3 (D1H2), Ac-α-tubulin (Lys40,
D20G3), α-tubulin (11H10) Ac-p53 (Lys382), pAkt
(Ser473, 193H12), Akt (40D4), Bcl-2 (50E3), p21 (12D1),
p27 (SX53G8.5), cyclin D1 (DCS6), PARP (46D11),
HDAC1 (10E2), HDAC2 (3F3), HDAC3 (7G6C), HDAC4
(D15C3), HDAC5 and HDAC6 (D2E5), all from Cell
Signaling Technology (Danvers, USA). Anti-p53 antibody
(C-11) that recognizes full-length p53 was purchased from
Santa Cruz Biotechnology (Santa Cruz, USA). The anti-
rabbit IgG and anti-mouse IgG secondary antibodies
were purchased from Cell Signaling Technology. Sig-
nals were developed with enhanced chemilumines-
cence substrates (Pierce Biotechnology) according to
the manufacturer’s protocols and visualized by Image Quant
LAS 4000 (GE Healthcare Biosciences AB, Uppsala, Sweden).
GAPDH (Proteintech Group, Chicago, USA) served as a
loading control.
Statistical analysis
All cell culture experiments were repeated three times
with similar results. Data were presented as mean ± SD.
Statistical comparisons were made using an unpaired 2-
tailed Student’s t-test between different groups. SPSS16.0
software (Chicago, USA) was used to perform statistical
analysis. Statistical significance was set at P value of < 0.05.
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